SIC
GLUE icon

SJS Investment Consulting’s Monte Rosa Therapeutics GLUE Stock Holding History

SJS Investment Consulting’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$630 Buy
26
+3
+13% +$57 ﹤0.01% 2190
2026
Q1 		$379 Sell
23
-6
-21% -$115 ﹤0.01% 1832
2025
Q4 		$455 Buy
+29
New +$391 ﹤0.01% 1562

Other funds holding GLUE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SJS Investment Consulting's GLUE Position: Q2 2026 in Review

SJS Investment Consulting increased its Monte Rosa Therapeutics (GLUE) stake by 13% in Q2 2026, buying an estimated $57 and bringing the position to 26 shares worth $630. The position accounts for ﹤0.01% of the portfolio, ranked #2190.

SJS Investment Consulting first reported a position in GLUE in Q4 2025 and has held it in 3 quarters since. 192 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • SJS Investment Consulting held 26 shares of Monte Rosa Therapeutics worth $630 as of Q2 2026.
  • SJS Investment Consulting bought 3 Monte Rosa Therapeutics shares in Q2 2026, an estimated $57.
  • Monte Rosa Therapeutics made up ﹤0.01% of SJS Investment Consulting's portfolio in Q2 2026, its #2190 holding.
  • SJS Investment Consulting first reported a position in Monte Rosa Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 192 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on SJS Investment Consulting's 13F filing for Q2 2026, filed 22 Jul 2026.